The Use of Dose Dense Rituximab for High Risk Patients With Newly Diagnosed Acute Immune Thrombocytopenic Purpura
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- To determine the Response Rate
研究概览
简要总结
The purpose of this study is to determine if a dose dense administration of Rituximab in newly diagnosed acute immune thrombocytopenic purpura (ITP) and determine relapse rate following this treatment.
Correlative studies will be performed as outlined in the appendices.
Quality of Life will be measured using the KIT as outlined in the protocol.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: Subjects must be ≥ 1 year and ≤ 21 years of age.
- •Diagnosis: Patients must have newly diagnosed ITP and a platelet count of ≤ 20 x 109 per Liter. Bone marrow aspirate and biopsy should be performed to rule out malignancy in the bone marrow.
- •High-risk features : In addition, patients must have one of more of the following high-risk criteria:
- •Age ≥ 10 years
- •Grade II-IV bleeding at diagnosis
- •ANA positivity
- •No history of preceding infection within 2 weeks prior to ITP diagnosis
- •Performance Status: Patients must have a performance status ≥ 50%. Use Karnofsky for patients > 16 years of age and Lansky for patients less than or equal to 16 years of age. See Appendix I for performance score.
- •Prior Therapy
- •Patients may not have received any treatment for ITP prior to start of therapy.
- •Patients may not receive systemic steroids ≥ 0.5 mg/kg prednisone (or equivalent) within 2 weeks prior to diagnosis.
- •Concomitant Medications Restrictions:
- •Steroids are only warranted as premedication prior to rituximab.
- •Patients who receive thrombopoetic agonists, eltrombopag or romiplostim will be taken off protocol.
- •Organ Function Requirements
- •Adequate Renal Function Defined As: estimated CrCl > 60 mL/min or >30% of GFR for age based on the Schwartz formula
- •Adequate Liver Function Defined As: AST and/or ALT less than 5 times the upper limit of normal, and/or direct bilirubin less than the 2 times of the upper limit of normal
排除标准
- •Patients with a history of Grade III-IV allergic reaction to rituximab
- •Patients with bone marrow neoplastic infiltration
- •Patients with a history of hepatitis B infection
- •Pregnancy and Breast Feeding
- •Female patients who are pregnant are ineligible (insert the reason: "due to risks of fetal and teratogenic adverse events as seen in animal/human studies" or "since there is yet no available information regarding human fetal or teratogenic toxicities").
- •Lactating females are not eligible unless they have agreed not to breastfeed their infants.
- •Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained.
研究组 & 干预措施
rituximab
All patients enrolled will receive the dose dense administration of rituximab. Five total doses will be administered on Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2
干预措施: rituxan (Drug)
结局指标
主要结局
To determine the Response Rate
时间窗: 1 year
To quantify remission rates for high-risk patients with acute ITP treated with a dose dense administration of rituximab.
To determine the safety events: Number of participants with treatment-related Grade III or higher adverse events as assessed by CTCAE v5.0.
时间窗: 1 year
To determine the occurrence of any Grade ≥ 3 non hematologic toxicity (per CTCAE v.5) which is possibly, probably, or definitely related to rituximab.
次要结局
未报告次要终点